MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Braco-19 trihydrochloride

CAS No. : 1177798-88-7

MCE 站：Braco-19 trihydrochloride

产品活性：Braco-19 trihydrochloride 是一种有效的端粒酶/端粒 (telomerase/telomere) 抑制剂，可防止端粒酶的催化作用。Braco-19 trihydrochloride 作为四联体 (GQ) 结合配体，稳定 GQ 四联体在 3V 端粒 DNA 处的形成，并可以导致快速衰老或选择性细胞死亡。Braco-19 trihydrochloride 也是一种HAdV病毒复制抑制剂。

研究领域：Cell Cycle/DNA Damage  |  Anti-infection

作用靶点：DNA/RNA Synthesis  |  CMV

In Vitro: Braco-19 trihydrochloride, as a well-known GQ binding ligand, interacts specifically with the HAdV GQs and increases their stability, and blocks the HAdV multiplication.
BRACO-19 trihydrochloride (1.0-10 μM; 5 day) cause zero growth inhibition is found 1 μM, the IC₅₀ for BRACO-19 in UXF1138L cells is 2.5 μM, the IC₁₀₀ is 5 μM.
BRACO-19 trihydrochloride (1 μM; 24 hours) shows dramatically reduced nuclear hTERT expression. However, residual cytoplasmic hTERT staining is observed accompanied by the occurrence of atypical mitoses.
BRACO-19 trihydrochloride (0-40 μM; 24 hours) decreases the AdV virus growth in a dose-dependent manner in eGFP-transinfected HEK 293 cells.
BRACO-19 trihydrochloride (0-150 μM; 24 hours) shows a decrease in band intensity in an increasing concentration-dependent manner.

In Vivo: BRACO-19 trihydrochloride (oral administration or intraperitoneal injection; 2 or 5 mg/kg; 3 weeks) oral dosing regimen are always inactive and the animals have to be sacrificed due to high tumor burden before overall termination of the study, Chronic, i.p. BRACO-19 administration, qdx5 is efficient in inhibiting tumor growth in earlystage xenografts but not advanced-stage xenografts.
BRACO-19 trihydrochloride (intraperitoneal injection; 2 mg/kg; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments) inhibits tumor growth significantly and under these conditions, marked single-agent antitumor activity is observed, with some animals in the group showing complete regressions (5 of 12 tumors).

相关产品：Cycloheximide  |  Oxaliplatin  |  Gemcitabine  |  Actinomycin D  |  Mitomycin C  |  Bleomycin sulfate  |  Carboplatin  |  Cytarabine  |  Favipiravir  |  Methotrexate  |  Streptozocin  |  Anisomycin  |  Fludarabine  |  Thymidine  |  Epirubicin hydrochloride  |  Daunorubicin hydrochloride  |  Capecitabine  |  Hydroxyurea  |  Plicamycin  |  Ganciclovir  |  Urolithin A  |  Brequinar  |  Folic acid  |  ML216  |  Halofugi  |  Floxuridine  |  Maribavir  |  Triciribine

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。